Acceptability of extending HPV-based cervical screening intervals from 3 to 5 years: an interview study with women in England. Issue 5 (4th May 2022)

• Record Type: Journal Article
• Authors: Nemec, Martin; Waller, Jo; Barnes, Jessica; Marlow, Laura A V
• Is Part Of: BMJ open. Volume 12:Issue 5(2022)
• Publication Date: 2022-05-04
• Subjects: public health -- gynaecology -- health policy -- epidemiology; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2021-058635
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Objectives: The introduction of primary Human Papillomavirus (HPV) testing in the National Health Service (NHS) Cervical Screening Programme in England means the screening interval for 25–49 years can be extended from 3 to 5 years. We explored women's responses to the proposed interval extension. Methods: We conducted semi-structured phone/video interviews with 22 women aged 25–49 years. Participants were selected to vary in age, socioeconomics and screening history. We explored attitudes to the current 3-year interval, then acceptability of a 5-year interval. Interviews were transcribed verbatim and analysed using framework analysis. Results: Attitudes to the current 3-year interval varied; some wanted more frequent screening, believing cancer develops quickly. Some participants worried about the proposed change; others trusted it was evidence based. Frequent questions concerned the rationale and safety of longer intervals, speed of cancer development, the possibility of HPV being missed or cell changes occurring between screens. Many participants felt reassured when the interval change was explained alongside the move to HPV primary screening, of which most had previously been unaware. Conclusions: Communication of the interval change should be done in the context of broader information about HPV primary screening, emphasising that people who test negative for HPV are at lower risk of cell changes so can safely be screened every 5 years. The long time needed for HPV to develop into cervical cancer provides reassurance about safety, but it is important to be transparent that no screening test is perfect.